Impact of cyp51A Mutations on the Pharmacokinetic and Pharmacodynamic Properties of Voriconazole in a Murine Model of Disseminated Aspergillosis

The in vivo efficacy of voriconazole against 4 clinical Aspergillus fumigatus isolates with MICs ranging from 0.125 to 2 mg/liter (CLSI document M38A) was assessed in a nonneutropenic murine model of disseminated aspergillosis. The study involved TR/L98H, M220I, and G54W mutants and a wild-type cont...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mavridou, Eleftheria, Bruggemann, Roger J. M., Melchers, Willem J. G., Verweij, Paul E., Mouton, Johan W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology (ASM) 2010
Assuntos:
Experimental Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2976127/
https://ncbi.nlm.nih.gov/pubmed/20733046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00606-10
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados